Skip to main content

Errata - English

PDF CSV May 14, 2022 through May 14, 2024 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Sort descending Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
<856> NEAR-INFRARED SPECTROSCOPY 4. VALIDATION AND VERIFICATION USP43–NF38 7161 1-May-2020 NA NA In 4.1 Validation/4.1.1 Accuracy/Validation criteria/Criteria 1: Change
Suitable agreement between SEP
to:
Suitable agreement between the standard error of prediction (SEP)
<1042> CELL BANKING PRACTICES FOR RECOMBINANT BIOLOGICS 5. CELL BANK CHARACTERIZATION USPNF Online Online 1-May-2023 NA NA In Table 4: Change
In vitro assayd,e + + +f
to:
In vitro assayd,e + −f +
<800> HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS 5. FACILITIES AND ENGINEERING CONTROLS/5.3 Compounding First Supplement to USP39–NF34 7721 1-Jun-2016 USP40–NF35 USP40–NF35 First bullet in second paragraph: Change
• Be externally vented through high-efficiency particulate air (HEPA) filtration
to:
• Be externally vented
<800> HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS 5. FACILITIES AND ENGINEERING CONTROLS/5.4 Containment Supplemental Engineering Controls First Supplement to USP40–NF35 Online 1-Dec-2017 USP42–NF37 Second Supplement to USP41–NF36 Line 5 of paragraph 1: Change
containment reduction.
to:
contamination reduction.
<855> NEPHELOMETRY AND TURBIDIMETRY 5. FORMAZIN TURBIDITY STANDARDS USP42–NF37 7059 1-May-2019 NA NA In paragraph 1: Change
IUPAC Compendium of Chemical Technology,
to:
IUPAC Compendium of Chemical Terminology,
<382> ELASTOMERIC COMPONENT FUNCTIONAL SUITABILITY IN PARENTERAL PRODUCT PACKAGING/DELIVERY SYSTEMS 5. NEEDLE AND SPIKE ACCESS FUNCTIONAL SUITABILITY TESTS Second Supplement to USP43–NF38 Online 1-Jan-2021 NA NA In paragraph 4 of 5.1 Fragmentation/Cartridge systems/Procedure A: Change
graticlule
to:
graticule
<1207> STERILE PRODUCT PACKAGING−INTEGRITY EVALUATION 5. PRODUCT–PACKAGE QUALITY REQUIREMENTS AND THE MAXIMUM ALLOWABLE LEAKAGE LIMIT/5.1 Sterility and Product Formulation Content must be Preserved; Gas Headspace Content Preservation is not Required First Supplement to USP39–NF34 7764 1-Dec-2016 USP41–NF36 Second Supplement to USP40–NF35 Line 3 of paragraph 5: Change
ultra-cold storage (<80°)
to:
ultra-cold storage (≤−80°)
<1092> THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION 6. ACCEPTANCE CRITERIA Second Supplement to USP43–NF38 Online 1-Dec-2020 NA NA In Row 1 of Table 5 and Table 6: Align Times with Acceptance Criteria
<1661> EVALUATION OF PLASTIC PACKAGING SYSTEMS AND THEIR MATERIALS OF CONSTRUCTION WITH RESPECT TO THEIR USER SAFETY IMPACT 6. APPLICABILITY AND APPLICATION OF <661.1> First Supplement to USP43–NF38 Online 1-Nov-2020 NA NA In 6.2 Application/6.2.5 Unaddressed Materials: Change
physiochemical
to:
physicochemical
<1430.5> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—SMALL ANGLE X-RAY SCATTERING AND SMALL ANGLE NEUTRON SCATTERING 6. EXPERIMENTAL CONSIDERATIONS Second Supplement to USP42–NF37 Online 1-Dec-2019 NA NA In 6.2 Resolution/6.2.1 Size resolution: Change
qmin < π/dmax π/dmax
to:
qmin < π/dmax
GENERAL NOTICES TO USP-NF 6. TESTING PRACTICES AND PROCEDURES/6.50. Preparation of Solutions First Supplement to USP37–NF32 6291 1-Aug-2014 USP38–NF33 USP38–NF33 Line 6 of 6.50.20. Solutions: Change
An expression such as “(1 in 10)” means that 1 part by volume of a liquid shall be diluted with a sufficient quantity of the diluent or solvent to make the volume of the finished solution 10 parts by volume. An expression such as “(20:5:2… Read More
<800> HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS 7. PERSONAL PROTECTIVE EQUIPMENT First Supplement to USP40–NF35 Online 1-Dec-2017 USP42–NF37 Second Supplement to USP41–NF36 Line 2 of paragraph 2: Change
antineoplastic HDs.
to:
injectable antineoplastic HDs.
BUFFER SOLUTIONS 4. Standard Buffer Solutions/4.1 Preparation Second Supplement to USP36–NF31 6244 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 1 of 4. Boric Acid and Potassium Chloride 0.2 M: Change
12.73 g/L of boric acid
to:
12.37 g/L of boric acid
FLUOCINONIDE TOPICAL SOLUTION Alcohol content USP36–NF31 3618 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 1 of Standard solution: Change
Dilute 20.0 mL of USP Alcohol
to:
Dilute 20.0 mL of alcohol
<208> ANTI-FACTOR XA AND ANTI-FACTOR IIA ASSAYS FOR UNFRACTIONATED AND LOW MOLECULAR WEIGHT HEPARINS Anti-Factor Xa and Anti-Factor IIa Assays for Low Molecular Weight Heparins USP43–NF38 6611 1-Aug-2020 NA NA Change
Anti-Factor Xa Activity for Low Molecular Weight Heparin
to:
The following procedure is used where specified in the individual monographs. This assay can be performed manually in plastic tubes utilizing heated block stations or water bath.… Read More
PRILOCAINE AND EPINEPHRINE INJECTION Assay for epinephrine USP35–NF30 4411 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 7 of Procedure: Change
183.21/333.30
to:
183.20/333.29
AND
Line 8 of Procedure: Change
183.21 and 333.30
to:
183.20 and 333.29
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE ACETATE OPHTHALMIC SUSPENSION Assay for hydrocortisone acetate USP41–NF36 2904 1-Nov-2018 USP43–NF38 Second Supplement to USP41–NF36 Line 1: Change
Proceed with Ophthalmic Suspension as directed in the Assay under Hydrocortisone Acetate Injectable Suspension.
to:
Standard preparation—Prepare as directed for Assay for… Read More
LIDOCAINE HYDROCHLORIDE AND DEXTROSE INJECTION Assay for lidocaine hydrochloride USPNF Online Online 1-Mar-2023 NA NA Change
Proceed with Injection as directed in the Assay for lidocaine hydrochloride under Lidocaine and Epinephrine Injection.
to:
Proceed with Injection as directed in the Assay for lidocaine hydrochloride under Lidocaine… Read More
POTASSIUM CHLORIDE, POTASSIUM BICARBONATE, AND POTASSIUM CITRATE EFFERVESCENT TABLETS FOR ORAL SOLUTION Assay for potassium USP36–NF31 4843 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Potassium stock solution and Standard preparations
to:
Standard stock solution and Standard solutions
AND
Line 1 of Procedure: Change
for Procedure in the Assay under Potassium Chloride Oral Solution.
Read More
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE FOR EFFERVESCENT ORAL SOLUTION Assay for potassium USP36–NF31 4834 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Potassium stock solution and Standard preparations
to:
Standard stock solution and Standard solutions
AND
Line 1 of Procedure: Change
for Procedure in the Assay under Potassium Chloride Oral Solution.
to… Read More
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE EFFERVESCENT TABLETS FOR ORAL SOLUTION Assay for potassium USP36–NF31 4834 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Potassium stock solution and Standard preparations
to:
Standard stock solution and Standard solutions
AND
Line 1 of Procedure: Change
for Procedure in the Assay under Potassium Chloride Oral Solution.
to… Read More
RIFAMPIN, ISONIAZID, PYRAZINAMIDE, AND ETHAMBUTOL HYDROCHLORIDE TABLETS Assay for rifampin, isoniazid, and pyrazinamide USP36–NF31 5047 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 12 of Procedure: Change
the Standard preparation and the Assay preparation, respectively.
to:
the Assay preparation and the Standard preparation, respectively.
Compound Undecylenic Acid Ointment Assay for zinc undecylenate USP35–NF30 4978 1-Dec-2012 USP37–NF32 Second Supplement to USP36–NF31 Line 17 of Procedure: Change
AU, AH, and AL
to:
AU, AS1, and AS2
COMPOUND UNDECYLENIC ACID OINTMENT Assay for zinc undecylenate USP36–NF31 5516 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 15 of Procedure: Change
431.94 is the molecular weight of zinc undecylenate;
to:
Mr is the molecular weight of zinc undecylenate, 431.94;
AND
Line 16 of Procedure: Change
65.39 is the atomic weight of zinc;
to:
Ar… Read More
MINOCYCLINE FOR INJECTION Assay USP36–NF31 4375 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride.
to:
Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate… Read More
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE ORAL SOLUTION Assay USP43–NF38 1438 1-Jul-2020 NA NA In Procedure: Change
(694.83/676.83)(25)CA(rU/rS)
in which 694.83 and 676.83 are the molecular weights of atropine sulfate monohydrate and anhydrous atropine sulfate,… Read More
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS Assay USP40–NF35 4710 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Change
Buffer solution, Mobile phase, Internal standard solution, Standard preparation, and Chromatographic system—Prepare as directed in the Assay under Diluted Isosorbide Dinitrate.
to:
Buffer solution—Dissolve 15.4 g of ammonium… Read More
CUPRIC SULFATE INJECTION Assay USP41–NF36 1112 1-Dec-2018 USP43–NF38 USP42–NF37 Line 8 of Assay preparation: Change
to bring the total sodium content of this flask to 13.5 mg.
to:
to bring the total sodium chloride content of this flask to 13.5 mg.
VERAPAMIL HYDROCHLORIDE ORAL SUSPENSION Assay USP36–NF31 5558 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2 of Mobile phase: Change
0.01 M
to:
0.01 N
AND
Line 7 of Assay preparation: Change
10-mL
to:
100-mL
MINOCYCLINE HYDROCHLORIDE ORAL SUSPENSION Assay USP36–NF31 4376 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Mobile phase and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride.
to:
Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180… Read More
POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES Assay USP36–NF31 4838 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Potassium stock solution and Standard preparations
to:
Standard stock solution and Standard solutions
AND
Line 1 of Procedure: Change
for Procedure in the Assay under Potassium Chloride Oral Solution.
Read More
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE TABLETS Assay USP43–NF38 1439 1-Jul-2020 NA NA In Procedure: Change
694.83/676.83)(250)CA(rU/rS)
in which 694.83 and 676.83 are the molecular weights of atropine sulfate monohydrate and anhydrous atropine sulfate,… Read More
RISPERIDONE TABLETS Assay USP38–NF33 5195 1-Feb-2016 USP40–NF35 Second Supplement to USP39–NF34 Line 4 of Procedure: Change
Calculate the quantity, in mg, of risperidone
to:
Calculate the percentage of the labeled amount of risperidone
DIAZEPAM INJECTION Assay USP39–NF34 3445 1-Jun-2016 USP40–NF35 USP40–NF35 Line 7 of Procedure:
50C / V(RU / RS)
to:
50(C / V)(RU / RS)
CAPTOPRIL ORAL SOLUTION Assay USP35–NF30 2477 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Mobile phase: Change
Prepare a filtered and degassed mixture of methanol and water (11:9) containing 0.5 mL of phosphoric acid.
to:
Methanol and water (55:45) containing 0.5 mL/L of phosphoric acid. Filter, and degas.
ATROPINE SULFATE TABLETS Assay USP35–NF30 2272 1-Apr-2013 USP37–NF32 USP37–NF32 Line 9 of Procedure: Change
RU and RS are as defined therein.
to:
RU and RS are the peak area ratios of atropine to homatropine.
THEOPHYLLINE TABLETS Assay USP43–NF38 4328 1-Sep-2020 NA NA Change
Mobile phase, Internal standard solution, and Standard preparation—Prepare as directed in the Assay under Theophylline.
to:
Buffer solution—Transfer 2.72 g of sodium acetate trihydrate to a 2000-mL… Read More
MINOCYCLINE HYDROCHLORIDE TABLETS Assay USP36–NF31 4378 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride.
to:
Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M… Read More
GRANISETRON HYDROCHLORIDE INJECTION Assay USP36–NF31 3772 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 10 of Procedure: Change
100(312.41 / 348.87)(C/L)(rU / rS)
to:
100(312.41 / 348.87)(C/CU)(rU / rS)
AND
Line of 14 of Procedure: Change
L is… Read More
FLUPHENAZINE DECANOATE INJECTION Assay USP36–NF31 3639 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 11 of Standard preparation: Delete
(1:5)
AND
Line 8 of Assay preparation: Delete
(1:5)
POTASSIUM CHLORIDE FOR ORAL SOLUTION Assay USP36–NF31 4840 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Potassium stock solution and Standard preparations
to:
Standard stock solution and Standard solutions
AND
Line 1 of Procedure: Change
for Procedure in the Assay under Potassium Chloride Oral Solution.
to… Read More
ISOSORBIDE DINITRATE SUBLINGUAL TABLETS Assay USP41–NF36 2272 1-May-2018 USP42–NF37 Second Supplement to USP41–NF36 Change
Buffer solution, Mobile phase, Internal standard solution, Standard preparation, and Chromatographic system—Prepare as directed in the Assay under Diluted Isosorbide Dinitrate.
to:
Buffer… Read More
CARTEOLOL HYDROCHLORIDE OPHTHALMIC SOLUTION Assay USP43–NF38 789 1-Sep-2020 NA NA Change
pH 6.0 buffer, Mobile phase, Diluent, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Carteolol Hydrochloride.
to:
Read More
MOXIFLOXACIN OPHTHALMIC SOLUTION Assay USP36–NF31 4414 1-Jun-2013 USP37–NF32 USP37–NF32 Line 4 of Resolution solution: Change
0.1 mg per mg and 0.001 mg per mg,
to:
0.1 mg per mL and 0.001 mg per mL,
CEFTAZIDIME FOR INJECTION Assay USP36–NF31 2887 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Line 6 of Procedure: Change
250,000[C/W (100 − ms)](rU / rS)
to:
25,000{C/[W (100 − ms)]}(rU / rS)
FUROSEMIDE TABLETS Assay USP43–NF38 2056 1-Aug-2020 NA NA Change:
Mobile phase, Diluting solution, System suitability solution, and Chromatographic system—Prepare as directed in the test for Related compounds under Furosemide.
to:
Mobile phase—Prepare a… Read More
DEXTROMETHORPHAN HYDROBROMIDE ORAL SOLUTION Assay USPNF Online Online 1-Sep-2023 NA NA In Chromatographic system and Procedure: Change
C is the concentration, in mg per mL, of USP Dextromethorphan Hydrobromide RS, on the anhydrous basis, in the Standard preparation;
to:
C is the concentration, in mg per mL… Read More
POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS Assay USP36–NF31 4841 1-Jun-2013 USP37–NF32 USP37–NF32 Line 5: Change
Potassium stock solution and Standard preparations
to:
Standard stock solution and Standard solutions
Line 1 of Procedure: Change
in the Assay under Potassium Chloride Oral Solution.
to:
for Instrumental… Read More
ISOSORBIDE DINITRATE TABLETS Assay USP41–NF36 2270 1-May-2018 USP42–NF37 Second Supplement to USP41–NF36 Change
Buffer solution, Mobile phase, Internal standard solution, Standard preparation, and Chromatographic system—Prepare as directed in the Assay under Diluted Isosorbide Dinitrate.
to:
Buffer… Read More
ONDANSETRON INJECTION Assay Second Supplement to USP36–NF31 Online 1-Apr-2014 USP38–NF33 USP38–NF33 Line 7 of Procedure: Change
(293.36 / 329.82)(25C / V)(rU / rS)
to:
(293.36 / 329.83)(25C / V)(rU / rS)
AND
Line 8 of Procedure: Change
329.82
to:
329.83